MYCN and neuroblastoma: In MYCN-nonamplified neuroblastomas, high c-MYC levels indicate an identical clinical outcome to that of MYCN-amplified, further proving their functional overlap [12] and establishing c-MYC as a hallmark of an unfavorable course of this cancer type [13].